Roflumilast is a phosphodiesterase‑4 (PDE4) inhibitor.
Its main, FDA‑approved use is to help people with severe chronic obstructive pulmonary disease (COPD) who have chronic bronchitis and a history of frequent exacerbations.
---
Why it’s used
| What it does | How it helps in COPD |
|--------------|---------------------|
| Reduces airway inflammation | By inhibiting PDE4, it raises intracellular cAMP, which dampens the production of pro‑inflammatory cytokines (e.g., TNF‑α, IL‑8). |
| Decreases exacerbations | Clinical trials show a ~20–30 % reduction in flare‑ups compared with placebo. |
| Improves lung function | Small, but clinically meaningful, improvements in FEV₁ and lung‑volume measures. |
| Enhances quality of life | Patients report better exercise tolerance and less dyspnea. |
---
Typical prescription
- Form: Oral tablet (500 µg or 250 µg once daily).
- Timing: Take with or without food; avoid taking with a high‑fat meal to ensure absorption.
- Add‑on therapy: Usually prescribed alongside inhaled corticosteroids (ICS) plus long‑acting bronchodilators. It’s not a replacement for inhalers.
---
Who should not take it?
| Contraindications / cautions | Reason |
|-----------------------------|--------|
| Severe liver disease | Roflumilast is metabolized by the liver; hepatic impairment can lead to elevated levels. |
| Recent pneumonia or severe infection | The drug can worsen infections or mask symptoms. |
| Unstable heart disease | Some patients experience palpitations or mild arrhythmias. |
| Pregnancy / breastfeeding | Limited data; generally avoided unless benefits outweigh risks. |
---
Common side effects
| Symptom | Frequency | Typical management |
|---------|-----------|--------------------|
| Nausea, vomiting, diarrhea | 10–30 % | Take with food, start low‑dose and titrate up, or consider temporary dose interruption. |
| Weight loss | 5–15 % | Encourage high‑calorie, protein‑rich diet; monitor BMI. |
| Insomnia / headache | 5–10 % | Adjust timing, use sleep hygiene measures. |
| Depression / mood changes | Rare (but reported) | Screen patients; consider psychiatric evaluation if symptoms arise. |
---
Off‑label / investigational uses
- Psoriasis: Topical roflumilast formulations are being studied.
- Crohn’s disease / ulcerative colitis: Small trials suggest anti‑inflammatory potential.
- Other inflammatory lung diseases: Not yet approved, but research is ongoing.
---
Bottom line
Roflumilast is not a rescue inhaler or a general COPD therapy. It’s specifically for patients with severe COPD + chronic bronchitis + frequent exacerbations, and is used to lower the risk of flare‑ups and modestly improve lung function. Talk to your provider about whether this add‑on makes sense for your situation and whether any monitoring or dose adjustments are needed.